Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Lexeo Therapeutics (LXEO) Income from Continuing Operations (2022 - 2026)

Lexeo Therapeutics' Income from Continuing Operations history spans 2 years, with the latest figure at 14187000.0 for Q4 2023.

  • On a quarterly basis, Income from Continuing Operations rose 2.68% to 14187000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was 66393000.0, a N/A change, with the full-year FY2025 number at 103222000.0, down 4.97% from a year prior.
  • Income from Continuing Operations hit 14187000.0 in Q4 2023 for Lexeo Therapeutics, up from 20108000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for LXEO hit a ceiling of 13441000.0 in Q2 2023 and a floor of 20108000.0 in Q3 2023.